Puma Biotechnology
Dennis Sanders - Senior Clinical Specialist - Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology Surging
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
Puma Biotechnology: Profitable, Troubled, But Worth A Good Look (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
Former Puma Biotech executive gets U.S. prison term for insider trading | Reuters
$16-$32/hr Puma Biotechnology Jobs (NOW HIRING) Mar 2024
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Puma Biotechnology, Inc. | CDISC
Puma Biotechnology
Articles about Puma Biotechnology
Puma Biotechnology unveils Phase II breast cancer trial design
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech's Stock Soars to New High, but Technical Analysis Signals Caution
Puma Biotechnology falls more than 20%
Puma Biotech's Breast Cancer Drug Results Mint New Billionaire Overnight
Puma Biotechnology
Puma Biotech agrees to pay investors $54.2 mln in fraud case | Reuters
Is Puma Biotechnology Inc (PBYI) Stock Over or Undervalued?
Why Puma Biotech Could Get Acquired Between July to September of This Year | BioSpace
A Top Puma Bio Exec Resigns Ahead of FDA Panel, Analysts Defend With Conflicting Stories - TheStreet
Strength Seen in Puma Biotech (PBYI): Can Its 10.0% Jump Turn into More Strength?
